We predict an enrichment in the number of tentative variants within RUNX3, a tumor suppressor, and SYF2, a cell cycle regulator, as targets for both P53 and cMYC, where the two genes play an important role in cancer progression [43, 44]. This evidence concerns the gene MYC and cancer.